1. Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 20145;9:e88323.
2. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46:S20-6.
4. Carmichael JA, Maskens PD. Cervical dysplasia and human papillomavirus. Am J Obstet Gynecol 1989;160:916-8.
8. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV): web annex C: evidence-to-decision framework for dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) [Internet]. Geneva: World Health Organization; c2024 [cited 2024 Aug 13]. Available from:
http://dx.doi.org/10.2471/b09020.
10. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15.
13. Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med 2020;20:186.
14. Dubel J, Dubel R, Ruszel K, Czekaj A, Namroży N. Vaccination against HPV (human papilloma virus) for women-why is it still recommended and not obligatory in Poland? J Educ Health Sport 2023;13:112-6.
15. Satanova AR, Kaidarova D, Kukubassov E, Bolatbekova R, Kaldybekov D, Bertleuov O. The global prevalence of human papillomavirus causing cervical cancer: a literature review. Oncol Radiol Kaz 2022;3:42-6.
16. López ED. Vaccination against human papillomavirus (HPV) in vulnerable populations - sexual minorities [Internet]. London: IntechOpen; c2022 [cited 2025 Jan 10]. Available from:
https://www.intechopen.com/chapters/80380.
19. Ai M. Relationship between human papillomavirus infection and cervical cancer progression. Infection International 2015;4:21-5.
20. Madhivanan P, Bokulich N, Coudray M, Colbert B, Ruiz-Perez D, Krupp K, et al. Composition of the vaginal microbiome associated with high risk HPV infection and increased risk for cervical cancer. Cancer Epidemiol Biomarkers Prev 2020;29:696.
26. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005;23:2388-94.
29. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 2006;44:1310-7.
32. Hoang HT, Ishizaki A, Nguyen CH, Tran VT, Matsushita K, Saikawa K, et al. Infection with high-risk HPV types among female sex workers in northern Vietnam. J Med Virol 2013;85:288-94.
33. Castle PE, Cremer M. Human papillomavirus testing in cervical cancer screening. Obstet Gynecol Clin North Am 2013;40:377-90.
34. Bai A, Xue P, Li Q, Jiang Y, Qiao Y. Diagnostic value of high-risk HPV other than type 16/18 in high-grade cervical neoplasia among cytology-negative women: a multicenter retrospective study. Cancer Med 2023;12:14794-805.
38. Sudhakaran S, Bhatla N, Mathur SR, Mahey R, Vashist S, Natarajan J, et al. Evaluation of cervical cancer screening during pregnancy in India: human papillomavirus testing can change the paradigm. Natl Med J India 2023;36:17-21.
40. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 2008;8:599-605.
42. Nakowong P, Chatchawal P, Chaibun T, Boonapatcharoen N, Promptmas C, Buajeeb W, et al. Detection of high-risk HPV 16 genotypes in cervical cancers using isothermal DNA amplification with electrochemical genosensor. Talanta 2024;269:125495.
44. Acevedo-Fontanez AI, Suarez E, Torres-Cintron CR, Ortiz AP. Abstract LB-166: risk of anal cancer in women with human papillomavirus-related gynecological neoplasm: puerto rico 1987-2013. Cancer Res 2017;77:LB-166.
49. Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J 2007;26:836-40.
50. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008;35:276-82.
54. Sehnal B, Podlešák T, Kmoníčková E, Nipčová M, Driák D, Sláma J, et al. Anogenital HPV infection as the potential risk factor for oropharyngeal carcinoma. Klin Onkol 2018;31:103-9.
56. Martínez-Gómez X, Curran A, Campins M, Alemany L, Rodrigo-Pendás JÁ, Borruel N, et al. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. Euro Surveill 2019;24:1700857.
60. Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine 2020;38:1302-14.
67. Konishi I. Precision medicine in gynecology and obstetrics. In: Ino K, editors. Prevention of cervical cancer: era of HPV testing and vaccination. 1st ed. Singapore: Springer Singapore; 2017. p. 87-99.
68. Elfström KM, Herweijer E, Sundström K, Arnheim-Dahlström L. Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review. Curr Opin Oncol 2014;26:120-9.
69. Snyman LC, Dreyer G, Botha MH, van der Merwe FH, Becker PJ. The vaccine and cervical cancer screen (VACCS) project: linking cervical cancer screening to HPV vaccination in the south-west district of Tshwane, Gauteng, South Africa. S Afr Med J 2015;105:115-20.
70. del Carmen MG. Cervical cancer: will interventions to HPV vaccination reduce disparities? Curr Women’s Health Rev 2018;14:235-41.
71. Silver MI, Kobrin S. Exacerbating disparities?: cervical cancer screening and HPV vaccination. Prev Med 2020;130:105902.
73. Murillo R, Ordóñez-Reyes C. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Int J Gynecol Cancer 2019;29:1317-26.
74. Diaz M, de Sanjose S, Ortendahl J, O’Shea M, Goldie SJ, Bosch FX, et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010;46:2973-85.
75. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007;111:145-53.
76. Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 Suppl 3:1-10.
77. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
78. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
80. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.
84. Thomas C. HPV vaccines: bring me your daughters! S Afr Med J 2008;98:259-61.
85. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, Rashidi BH, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature. Gynecol Oncol 2013;128:277-81.
87. Zhang L, Zhou F, Zhao KN. Molecular approaches target to immunotherapy for HPV-associated cancers. Curr Cancer Drug Targets 2017;17:512-21.
88. Zoa Assoumou S, Ndjoyi Mbiguino A, Mabika Mabika B, Nguizi Ogoula S, El Mzibri M, Khattabi A, et al. Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities. Infect Agent Cancer 2016;11:2.
90. Arora S, Ramachandra SS, Squier C. Knowledge about human papillomavirus (HPV) related oral cancers among oral health professionals in university setting-a cross sectional study. J Oral Biol Craniofac Res 2018;8:35-9.
93. Lin YY, Alphs H, Hung CF, Roden RB, Wu TC. Vaccines against human papillomavirus. Front Biosci 2007;12:246-64.
94. Gohar A, Ali AA, Elkhatib WF, El-Sayyad GS, Elfadil D, Noreddin AM. Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology. Microb Pathog 2022;171:105747.
95. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;31 Suppl 5:F1-31.
96. Ino K. Prevention of cervical cancer: era of HPV testing and vaccination. In: Ino K, editor. Precision medicine in gynecology and obstetrics. Singapore: Springer; 2017. p.87-99.
98. Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine 2012;30Suppl 5:F1-11.
99. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007;107:S19-23.
100. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol 2009;114:395-8.
101. Phoolcharoen N, Baker ES, Salcedo MP. Cervical cancer screening. 2nd ed. Cham: Springer International Publishing; 2021.
103. Saraiya M, Steben M, Watson M, Markowitz L. Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians. Prev Med 2013;57:426-33.